Advertisement
10-04-2025 | Geriatric Assessment | REVIEW
Role of Geriatric Assessment in Hematopoietic Stem Cell Transplant and Cellular Therapies
Published in: Current Treatment Options in Oncology
Login to get accessPlease log in to get access to this content
Literature
1.
go back to reference World Health Organization: Ageing and health, 1 Oct 2024. https://www.who.int/news-room/fact-sheets/detail/ageing-and-health#:~:text=By. Accessed Dec 18 2024
World Health Organization: Ageing and health, 1 Oct 2024. https://www.who.int/news-room/fact-sheets/detail/ageing-and-health#:~:text=By. Accessed Dec 18 2024
2.
go back to reference American Cancer Society: Cancer Facts and Figures 2024. American Cancer Society, 2024.Available online. Accessed June 21, 2024.
American Cancer Society: Cancer Facts and Figures 2024. American Cancer Society, 2024.Available online. Accessed June 21, 2024.
3.
go back to reference Surveillance, Epidemiology, and End Results Program: Cancer Stat Facts:. Available online. https://seer.cancer.gov/statistics-network/explorer. Accessed Dec 5, 2024.
Surveillance, Epidemiology, and End Results Program: Cancer Stat Facts:. Available online. https://seer.cancer.gov/statistics-network/explorer. Accessed Dec 5, 2024.
4.
go back to reference Cusatis R, Litovich C, Feng Z, et al. Current trends and outcomes in cellular therapy activity in the United States, including prospective Patient Reported Outcomes data collection within the CIBMTR registry. Transplant Cell Ther. 2024;S2666–6367(24):00482–92. https://doi.org/10.1016/j.jtct.2024.06.021.CrossRef
Cusatis R, Litovich C, Feng Z, et al. Current trends and outcomes in cellular therapy activity in the United States, including prospective Patient Reported Outcomes data collection within the CIBMTR registry. Transplant Cell Ther. 2024;S2666–6367(24):00482–92. https://doi.org/10.1016/j.jtct.2024.06.021.CrossRef
5.
go back to reference Jain MD, Spiegel JY, Nastoupil LJ, et al. Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2024;42(30):3581–92. https://doi.org/10.1200/JCO.23.02786.CrossRefPubMed
Jain MD, Spiegel JY, Nastoupil LJ, et al. Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2024;42(30):3581–92. https://doi.org/10.1200/JCO.23.02786.CrossRefPubMed
6.
go back to reference Palomba ML, Crombie JL, Nastoupil LJ, et al. Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US) Transplantation and Cellular Therapy. Blood. 2024;30(2):S40–1. https://doi.org/10.1016/j.jtct.2023.12.071.CrossRef
Palomba ML, Crombie JL, Nastoupil LJ, et al. Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US) Transplantation and Cellular Therapy. Blood. 2024;30(2):S40–1. https://doi.org/10.1016/j.jtct.2023.12.071.CrossRef
7.
go back to reference Lemoine J, Bachy E, Cartron G, et al. Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry. Blood Adv. 2023;7(21):6589–98. https://doi.org/10.1182/bloodadvances.2023010624.CrossRefPubMedPubMedCentral
Lemoine J, Bachy E, Cartron G, et al. Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry. Blood Adv. 2023;7(21):6589–98. https://doi.org/10.1182/bloodadvances.2023010624.CrossRefPubMedPubMedCentral
8.
go back to reference Ustun C, Le-Rademacher J, Wang HL, et al. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia. 2019;33(11):2599–609. https://doi.org/10.1038/s41375-019-0477-x.CrossRefPubMedPubMedCentral
Ustun C, Le-Rademacher J, Wang HL, et al. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia. 2019;33(11):2599–609. https://doi.org/10.1038/s41375-019-0477-x.CrossRefPubMedPubMedCentral
9.
go back to reference Versluis J, Hazenberg CL, Passweg JR, HOVON and SAKK Leukemia Groups. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. Lancet Haematol. 2015;2(10):427–36. https://doi.org/10.1016/S2352-3026(15)00148-9.CrossRef
Versluis J, Hazenberg CL, Passweg JR, HOVON and SAKK Leukemia Groups. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. Lancet Haematol. 2015;2(10):427–36. https://doi.org/10.1016/S2352-3026(15)00148-9.CrossRef
10.
go back to reference Nakamura R, Saber W, Martens MJ, et al. Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50–75 years of age with advanced myelodysplastic syndrome. J Clin Oncol. 2021;39(30):3328–39. https://doi.org/10.1200/JCO.20.03380.CrossRefPubMedPubMedCentral
Nakamura R, Saber W, Martens MJ, et al. Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50–75 years of age with advanced myelodysplastic syndrome. J Clin Oncol. 2021;39(30):3328–39. https://doi.org/10.1200/JCO.20.03380.CrossRefPubMedPubMedCentral
11.
go back to reference Russell NH, Hills RK, Thomas A, et al. Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial. Haematologica. 2022;107(7):1518–27. https://doi.org/10.3324/haematol.2021.279010.CrossRefPubMed
Russell NH, Hills RK, Thomas A, et al. Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial. Haematologica. 2022;107(7):1518–27. https://doi.org/10.3324/haematol.2021.279010.CrossRefPubMed
12.
go back to reference Houot R, Bachy E, Cartron G, et al. Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nat Med. 2023;29(10):2593–601. https://doi.org/10.1038/s41591-023-02572-5.CrossRefPubMedPubMedCentral
Houot R, Bachy E, Cartron G, et al. Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nat Med. 2023;29(10):2593–601. https://doi.org/10.1038/s41591-023-02572-5.CrossRefPubMedPubMedCentral
13.
go back to reference Westin JR, Oluwole OO, Kersten MJ, et al. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. N Engl J Med. 2023;389(2):148–57.CrossRefPubMed
Westin JR, Oluwole OO, Kersten MJ, et al. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. N Engl J Med. 2023;389(2):148–57.CrossRefPubMed
14.
go back to reference Sehgal A, Hoda D, Riedell PA, et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022;23(8):1066–77. https://doi.org/10.1016/S1470-2045(22)00339-4.CrossRefPubMed
Sehgal A, Hoda D, Riedell PA, et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022;23(8):1066–77. https://doi.org/10.1016/S1470-2045(22)00339-4.CrossRefPubMed
15.
go back to reference Neelapu SS, Jacobson CA, Oluwole OO, et al. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2020;135(23):2106–9. https://doi.org/10.1182/blood.2019004162.CrossRefPubMedPubMedCentral
Neelapu SS, Jacobson CA, Oluwole OO, et al. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2020;135(23):2106–9. https://doi.org/10.1182/blood.2019004162.CrossRefPubMedPubMedCentral
16.
go back to reference Kalariya NM, Hildebrandt MAT, Hansen DK, et al. Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience. Blood Adv. 2024;8(17):4679–88. https://doi.org/10.1182/bloodadvances.2024013540.CrossRefPubMedPubMedCentral
Kalariya NM, Hildebrandt MAT, Hansen DK, et al. Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience. Blood Adv. 2024;8(17):4679–88. https://doi.org/10.1182/bloodadvances.2024013540.CrossRefPubMedPubMedCentral
17.
go back to reference Mrózek K, Kohlschmidt J, Blachly JS, et al. Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study. Leukemia. 2023;37(4):788–98. https://doi.org/10.1038/s41375-023-01846-8.CrossRefPubMedPubMedCentral
Mrózek K, Kohlschmidt J, Blachly JS, et al. Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study. Leukemia. 2023;37(4):788–98. https://doi.org/10.1038/s41375-023-01846-8.CrossRefPubMedPubMedCentral
18.
go back to reference Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291(22):2720–6. https://doi.org/10.1001/jama.291.22.2720.CrossRefPubMed
Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291(22):2720–6. https://doi.org/10.1001/jama.291.22.2720.CrossRefPubMed
19.
go back to reference Ludmir EB, Mainwaring W, Lin TA, et al. Factors associated with age disparities among cancer clinical trial participants. JAMA Oncol. 2019;5(12):1769–73. https://doi.org/10.1001/jamaoncol.2019.2055.CrossRefPubMed
Ludmir EB, Mainwaring W, Lin TA, et al. Factors associated with age disparities among cancer clinical trial participants. JAMA Oncol. 2019;5(12):1769–73. https://doi.org/10.1001/jamaoncol.2019.2055.CrossRefPubMed
20.
go back to reference Flannelly C, Tan BE, Tan JL, et al. Barriers to hematopoietic cell transplantation for adults in the united states: a systematic review with a focus on Age. Biol Blood Marrow Transplant. 2020;26(12):2335–45. https://doi.org/10.1016/j.bbmt.2020.09.013.CrossRefPubMedPubMedCentral
Flannelly C, Tan BE, Tan JL, et al. Barriers to hematopoietic cell transplantation for adults in the united states: a systematic review with a focus on Age. Biol Blood Marrow Transplant. 2020;26(12):2335–45. https://doi.org/10.1016/j.bbmt.2020.09.013.CrossRefPubMedPubMedCentral
21.
go back to reference Pidala J, Craig BM, Lee SJ, et al. Practice variation in physician referral for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2013;48(1):63–7. https://doi.org/10.1038/bmt.2012.95.CrossRefPubMed
Pidala J, Craig BM, Lee SJ, et al. Practice variation in physician referral for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2013;48(1):63–7. https://doi.org/10.1038/bmt.2012.95.CrossRefPubMed
22.
go back to reference Tomlinson B, de Lima M, Cogle CR, et al. Transplantation referral patterns for patients with newly diagnosed higher-risk myelodysplastic syndromes and acute myeloid leukemia at academic and community sites in the connect® myeloid disease registry: potential barriers to care. Transplant Cell Ther. 2023;29(7):460.e1-460.e9. https://doi.org/10.1016/j.jtct.2023.04.011.CrossRefPubMed
Tomlinson B, de Lima M, Cogle CR, et al. Transplantation referral patterns for patients with newly diagnosed higher-risk myelodysplastic syndromes and acute myeloid leukemia at academic and community sites in the connect® myeloid disease registry: potential barriers to care. Transplant Cell Ther. 2023;29(7):460.e1-460.e9. https://doi.org/10.1016/j.jtct.2023.04.011.CrossRefPubMed
23.
go back to reference Hoffmann MS, Hunter BD, Cobb PW, et al. Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed/refractory diffuse large b cell lymphoma. Transplant Cell Ther. 2023;29(7):440–8. https://doi.org/10.1016/j.jtct.2023.04.003.CrossRefPubMed
Hoffmann MS, Hunter BD, Cobb PW, et al. Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed/refractory diffuse large b cell lymphoma. Transplant Cell Ther. 2023;29(7):440–8. https://doi.org/10.1016/j.jtct.2023.04.003.CrossRefPubMed
24.
go back to reference Sorror ML, Sandmaier BM, Storer BE, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA. 2011;306(17):1874–83. https://doi.org/10.1001/jama.2011.1558.CrossRefPubMedPubMedCentral
Sorror ML, Sandmaier BM, Storer BE, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA. 2011;306(17):1874–83. https://doi.org/10.1001/jama.2011.1558.CrossRefPubMedPubMedCentral
25.
go back to reference Ringdén O, Boumendil A, Labopin M, et al. Outcome of allogeneic hematopoietic stem cell transplantation in patients Age >69 years with acute myelogenous leukemia: on behalf of the acute leukemia working party of the european society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2019;25(10):1975–83. https://doi.org/10.1016/j.bbmt.2019.05.037.CrossRefPubMed
Ringdén O, Boumendil A, Labopin M, et al. Outcome of allogeneic hematopoietic stem cell transplantation in patients Age >69 years with acute myelogenous leukemia: on behalf of the acute leukemia working party of the european society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2019;25(10):1975–83. https://doi.org/10.1016/j.bbmt.2019.05.037.CrossRefPubMed
26.
go back to reference Schetelig J, Bornhäuser M, Schmid C, et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol. 2008;26(32):5183–91. https://doi.org/10.1200/JCO.2007.15.5184.CrossRefPubMed
Schetelig J, Bornhäuser M, Schmid C, et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol. 2008;26(32):5183–91. https://doi.org/10.1200/JCO.2007.15.5184.CrossRefPubMed
27.
go back to reference Hsu J, Chen Z, Shore T, et al. Outcomes of allogeneic stem cell transplant for elderly patients with hematologic malignancies. Biol Blood Marrow Transplant. 2020;26(4):789–97. https://doi.org/10.1016/j.bbmt.2019.12.766.CrossRefPubMed
Hsu J, Chen Z, Shore T, et al. Outcomes of allogeneic stem cell transplant for elderly patients with hematologic malignancies. Biol Blood Marrow Transplant. 2020;26(4):789–97. https://doi.org/10.1016/j.bbmt.2019.12.766.CrossRefPubMed
28.
go back to reference Sorror ML, Logan BR, Zhu X, et al. Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant. 2015;21(8):1479–87. https://doi.org/10.1016/j.bbmt.2015.04.004.CrossRefPubMedPubMedCentral
Sorror ML, Logan BR, Zhu X, et al. Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant. 2015;21(8):1479–87. https://doi.org/10.1016/j.bbmt.2015.04.004.CrossRefPubMedPubMedCentral
29.
go back to reference Backhaus D, Brauer D, Pointner R, et al. A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older. Bone Marrow Transplant. 2023;58(1):30–8. https://doi.org/10.1038/s41409-022-01833-0.CrossRefPubMed
Backhaus D, Brauer D, Pointner R, et al. A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older. Bone Marrow Transplant. 2023;58(1):30–8. https://doi.org/10.1038/s41409-022-01833-0.CrossRefPubMed
30.
go back to reference Polverelli N, Tura P, Battipaglia G, et al. Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation A French-Italian 10-year experience on 228 patients. Bone Marrow Transplant. 2020;55(12):2224–33. https://doi.org/10.1038/s41409-020-0934-1.CrossRefPubMed
Polverelli N, Tura P, Battipaglia G, et al. Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation A French-Italian 10-year experience on 228 patients. Bone Marrow Transplant. 2020;55(12):2224–33. https://doi.org/10.1038/s41409-020-0934-1.CrossRefPubMed
31.
go back to reference Soriano RP (2007) The comprehensive geriatric assessment. In: Soriano, R.P., Fernandez, H.M., Cassel, C.K., Leipzig, R.M. (eds) Fundamentals of geriatric medicine. Springer, New York, NY. https://doi.org/10.1007/978-0-387-32326-8_2
Soriano RP (2007) The comprehensive geriatric assessment. In: Soriano, R.P., Fernandez, H.M., Cassel, C.K., Leipzig, R.M. (eds) Fundamentals of geriatric medicine. Springer, New York, NY. https://doi.org/10.1007/978-0-387-32326-8_2
32.
go back to reference Magnuson A, Loh KP, Stauffer F, et al. Geriatric assessment for the practicing clinician: The why, what, and how. CA Cancer J Clin. 2024;74(6):496–518. https://doi.org/10.3322/caac.21864.CrossRefPubMed
Magnuson A, Loh KP, Stauffer F, et al. Geriatric assessment for the practicing clinician: The why, what, and how. CA Cancer J Clin. 2024;74(6):496–518. https://doi.org/10.3322/caac.21864.CrossRefPubMed
33.
go back to reference Extermann M, Artz A, Rebollo MA, et al. Treating acute myeloge nous leukemia in patients aged 70 and above: recommendations from the International Society of Geriatric Oncology (SIOG). J Geriatr Oncol. 2024;15(2): 101626. https://doi.org/10.1016/j.jgo.2023.101626.CrossRefPubMed
Extermann M, Artz A, Rebollo MA, et al. Treating acute myeloge nous leukemia in patients aged 70 and above: recommendations from the International Society of Geriatric Oncology (SIOG). J Geriatr Oncol. 2024;15(2): 101626. https://doi.org/10.1016/j.jgo.2023.101626.CrossRefPubMed
34.
go back to reference Stauder R, Eichhorst B, Hamaker ME, et al. Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force. Ann Oncol. 2017;28(2):218–27. https://doi.org/10.1093/annonc/mdw547.CrossRefPubMed
Stauder R, Eichhorst B, Hamaker ME, et al. Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force. Ann Oncol. 2017;28(2):218–27. https://doi.org/10.1093/annonc/mdw547.CrossRefPubMed
35.
go back to reference Wildes TM, Artz AS. Characterize, optimize, and harmonize: caring for older adults with hematologic malignancies. Am Soc Clin Oncol Educ Book. 2021;41:1–9. https://doi.org/10.1200/EDBK_320141.CrossRefPubMed
Wildes TM, Artz AS. Characterize, optimize, and harmonize: caring for older adults with hematologic malignancies. Am Soc Clin Oncol Educ Book. 2021;41:1–9. https://doi.org/10.1200/EDBK_320141.CrossRefPubMed
36.
go back to reference Disalvo D, Moth E, Soo WK, et al. The effect of comprehensive geriatric assessment on care received, treatment completion, toxicity, cancer-related and geriatric assessment outcomes, and quality of life for older adults receiving systemic anti-cancer treatment: A systematic review. J Geriat Oncol. 2023;14(8):101585. https://doi.org/10.1016/j.jgo.2023.101585.CrossRef
Disalvo D, Moth E, Soo WK, et al. The effect of comprehensive geriatric assessment on care received, treatment completion, toxicity, cancer-related and geriatric assessment outcomes, and quality of life for older adults receiving systemic anti-cancer treatment: A systematic review. J Geriat Oncol. 2023;14(8):101585. https://doi.org/10.1016/j.jgo.2023.101585.CrossRef
37.
go back to reference Mohile SG, Mohamed MR, Xu H, et al. Evaluation of geriatric assess ment and management on the toxic effects of cancer treatment (GAP70þ): a cluster-randomised study. Lancet. 2021;398(10314):1894–904. https://doi.org/10.1016/S0140-6736(21)01789-X.CrossRefPubMedPubMedCentral
Mohile SG, Mohamed MR, Xu H, et al. Evaluation of geriatric assess ment and management on the toxic effects of cancer treatment (GAP70þ): a cluster-randomised study. Lancet. 2021;398(10314):1894–904. https://doi.org/10.1016/S0140-6736(21)01789-X.CrossRefPubMedPubMedCentral
38.
go back to reference Mohile SG, Epstein RM, Hurria A, et al. Communication with older patients with cancer using geriatric assessment: a cluster-randomized clinical trial from the National Cancer Institute Community Oncology Research Program. JAMA Oncol. 2020;6(2):196–204. https://doi.org/10.1001/jamaoncol.2019.4728.CrossRefPubMed
Mohile SG, Epstein RM, Hurria A, et al. Communication with older patients with cancer using geriatric assessment: a cluster-randomized clinical trial from the National Cancer Institute Community Oncology Research Program. JAMA Oncol. 2020;6(2):196–204. https://doi.org/10.1001/jamaoncol.2019.4728.CrossRefPubMed
39.
go back to reference Soo WK, King MT, Pope A, Parente P, Darzin ¸s P, Davis ID. Integrated geriatric assessment and treatment effectiveness (INTEGERATE) in older people with cancer starting systemic anticancer treatment in Australia: a multicentre, open-label, randomised controlled trial. Lancet Healthy Longev. 2022;3(9):e617–27. https://doi.org/10.1016/S2666-7568(22)00169-6.CrossRefPubMed
Soo WK, King MT, Pope A, Parente P, Darzin ¸s P, Davis ID. Integrated geriatric assessment and treatment effectiveness (INTEGERATE) in older people with cancer starting systemic anticancer treatment in Australia: a multicentre, open-label, randomised controlled trial. Lancet Healthy Longev. 2022;3(9):e617–27. https://doi.org/10.1016/S2666-7568(22)00169-6.CrossRefPubMed
40.
go back to reference Dale W, Klepin HD, Williams GR, et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update. J Clin Oncol. 2023;41(26):4293–312. https://doi.org/10.1200/JCO.23.00933.CrossRefPubMed
Dale W, Klepin HD, Williams GR, et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update. J Clin Oncol. 2023;41(26):4293–312. https://doi.org/10.1200/JCO.23.00933.CrossRefPubMed
41.
go back to reference Puts M, Alqurini N, Strohschein F, et al. Impact of geriatric assessment and management on quality of life, unplanned hospitalizations, toxicity, and survival for older adults with cancer: the randomized 5C Trial. J Clin Oncol. 2023;41(4):847–58. https://doi.org/10.1200/JCO.22.01007.CrossRefPubMed
Puts M, Alqurini N, Strohschein F, et al. Impact of geriatric assessment and management on quality of life, unplanned hospitalizations, toxicity, and survival for older adults with cancer: the randomized 5C Trial. J Clin Oncol. 2023;41(4):847–58. https://doi.org/10.1200/JCO.22.01007.CrossRefPubMed
42.
go back to reference Lund CM, Vistisen KK, Olsen AP, et al. 2021) The effect of geriatric intervention in frail older patients receiving chemotherapy for colorectal cancer: a randomised trial (GERICO. Br J Cancer. 1958;124(12):1949. https://doi.org/10.1038/s41416-021-01367-0.CrossRef
Lund CM, Vistisen KK, Olsen AP, et al. 2021) The effect of geriatric intervention in frail older patients receiving chemotherapy for colorectal cancer: a randomised trial (GERICO. Br J Cancer. 1958;124(12):1949. https://doi.org/10.1038/s41416-021-01367-0.CrossRef
43.
go back to reference DuMontier C, Uno H, Hshieh T, et al. Randomized controlled trial of geriatric consultation versus standard care in older adults with hematologic malignancies. Haematologica. 2022;107(5):1172–80. https://doi.org/10.3324/haematol.2021.278802.CrossRefPubMed
DuMontier C, Uno H, Hshieh T, et al. Randomized controlled trial of geriatric consultation versus standard care in older adults with hematologic malignancies. Haematologica. 2022;107(5):1172–80. https://doi.org/10.3324/haematol.2021.278802.CrossRefPubMed
44.
go back to reference Anwar MR, Yeretzian ST, Ayala AP, et al. Effectiveness of geriatric assessment and management in older cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2023;115(12):1483–96. https://doi.org/10.1093/jnci/djad200.CrossRefPubMed
Anwar MR, Yeretzian ST, Ayala AP, et al. Effectiveness of geriatric assessment and management in older cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2023;115(12):1483–96. https://doi.org/10.1093/jnci/djad200.CrossRefPubMed
45.
go back to reference Chuang MH, Chen JY, Tsai WW, et al. Impact of comprehensive geriatric assessment on the risk of adverse events in the older patients receiving anti-cancer therapy: a systematic review and meta-analysis. Age Ageing. 2022;51(7):afac145. https://doi.org/10.1093/ageing/afac145.CrossRefPubMed
Chuang MH, Chen JY, Tsai WW, et al. Impact of comprehensive geriatric assessment on the risk of adverse events in the older patients receiving anti-cancer therapy: a systematic review and meta-analysis. Age Ageing. 2022;51(7):afac145. https://doi.org/10.1093/ageing/afac145.CrossRefPubMed
46.
go back to reference Disalvo D, Moth E, Soo WK, et al. The effect of comprehensive geriatric assessment on care received, treatment completion, toxicity, cancer related and geriatric assessment outcomes, and quality of life for older adults receiving systemic anti-cancer treatment:a systematic review. J Geriatr Oncol. 2023;14(8):101585. https://doi.org/10.1016/j.jgo.2023.101585.CrossRefPubMed
Disalvo D, Moth E, Soo WK, et al. The effect of comprehensive geriatric assessment on care received, treatment completion, toxicity, cancer related and geriatric assessment outcomes, and quality of life for older adults receiving systemic anti-cancer treatment:a systematic review. J Geriatr Oncol. 2023;14(8):101585. https://doi.org/10.1016/j.jgo.2023.101585.CrossRefPubMed
47.
go back to reference Lin RJ, Elko TA, Devlin SM, et al. Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies. Bone Marrow Transplant. 2020;55(1):157–64. https://doi.org/10.1038/s41409-019-0654-6.CrossRefPubMed
Lin RJ, Elko TA, Devlin SM, et al. Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies. Bone Marrow Transplant. 2020;55(1):157–64. https://doi.org/10.1038/s41409-019-0654-6.CrossRefPubMed
48.
go back to reference Sugidono M, Lo M, Young R, et al. Impact of polypharmacy prior to allogeneic hematopoietic stem cell transplantation in older Adults. Transplant Cell Ther. 2021;27(4):344.e1-344.e5. https://doi.org/10.1016/j.jtct.2021.01.001.CrossRefPubMed
Sugidono M, Lo M, Young R, et al. Impact of polypharmacy prior to allogeneic hematopoietic stem cell transplantation in older Adults. Transplant Cell Ther. 2021;27(4):344.e1-344.e5. https://doi.org/10.1016/j.jtct.2021.01.001.CrossRefPubMed
49.
go back to reference Muffly LS, Kocherginsky M, Stock W, et al. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014;99(8):1373–9. https://doi.org/10.3324/haematol.2014.103655.CrossRefPubMedPubMedCentral
Muffly LS, Kocherginsky M, Stock W, et al. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014;99(8):1373–9. https://doi.org/10.3324/haematol.2014.103655.CrossRefPubMedPubMedCentral
50.
go back to reference Huang LW, Sheng Y, Andreadis C, et al. Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplantation recipients. Biol Blood Marrow Transplant. 2020;26(1):189–96. https://doi.org/10.1016/j.bbmt.2019.08.022.CrossRefPubMed
Huang LW, Sheng Y, Andreadis C, et al. Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplantation recipients. Biol Blood Marrow Transplant. 2020;26(1):189–96. https://doi.org/10.1016/j.bbmt.2019.08.022.CrossRefPubMed
51.
go back to reference Salas MQ, Atenafu EG, Bascom O, et al. Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021;56(1):60–9. https://doi.org/10.1038/s41409-020-0979-1.CrossRefPubMed
Salas MQ, Atenafu EG, Bascom O, et al. Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021;56(1):60–9. https://doi.org/10.1038/s41409-020-0979-1.CrossRefPubMed
52.
go back to reference Salas MQ, Atenafu EG, Pasic I, et al. HCT frailty scale for younger and older adults undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2023;58(11):1237–46. https://doi.org/10.1038/s41409-023-02088-z.CrossRefPubMed
Salas MQ, Atenafu EG, Pasic I, et al. HCT frailty scale for younger and older adults undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2023;58(11):1237–46. https://doi.org/10.1038/s41409-023-02088-z.CrossRefPubMed
53.
go back to reference Artz A, Logan BR, Saber W, et al. The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) among older recipients of allogeneic transplantation: A Prospective BMT-CTN Study 1704. Blood. 2023;142(1):109. https://doi.org/10.1182/blood-2023-173855.CrossRef
Artz A, Logan BR, Saber W, et al. The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) among older recipients of allogeneic transplantation: A Prospective BMT-CTN Study 1704. Blood. 2023;142(1):109. https://doi.org/10.1182/blood-2023-173855.CrossRef
54.
go back to reference Sorror M, Saber W, Logan BR, et al. The Composite Health Risk Assessment Model (CHARM) Predicts Risks of Toxicities, Functional and Cognitive Decline Among Survivors of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): A Prospective BMT-CTN Study 1704. Blood. 2024;144(Supplement 1):685. https://doi.org/10.1182/blood-2024-194414.CrossRef
Sorror M, Saber W, Logan BR, et al. The Composite Health Risk Assessment Model (CHARM) Predicts Risks of Toxicities, Functional and Cognitive Decline Among Survivors of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): A Prospective BMT-CTN Study 1704. Blood. 2024;144(Supplement 1):685. https://doi.org/10.1182/blood-2024-194414.CrossRef
55.
go back to reference Salas MQ, Solano MT, González MB, et al. The impact of frailty on outcomes and quality of life in allogeneic hematopoietic cell transplantation: summary of results from a collaborative prospective study conducted on behalf of the Geth-TC. Blood. 2024;144(Supplement 1):405. https://doi.org/10.1182/blood-2024-210022.CrossRef
Salas MQ, Solano MT, González MB, et al. The impact of frailty on outcomes and quality of life in allogeneic hematopoietic cell transplantation: summary of results from a collaborative prospective study conducted on behalf of the Geth-TC. Blood. 2024;144(Supplement 1):405. https://doi.org/10.1182/blood-2024-210022.CrossRef
56.
go back to reference Roy I, Smilnak G, Burkart M, et al. Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Br J Haematol. 2022;197(1):71–5. https://doi.org/10.1111/bjh.18054.CrossRefPubMed
Roy I, Smilnak G, Burkart M, et al. Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Br J Haematol. 2022;197(1):71–5. https://doi.org/10.1111/bjh.18054.CrossRefPubMed
57.
go back to reference Rejeski K, Cordas Dos Santos DM, Parker NH, et al. Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy. Cancer Immunol Res. 2023;11(6):707–19. https://doi.org/10.1158/2326-6066.CIR-22-0487.CrossRefPubMedPubMedCentral
Rejeski K, Cordas Dos Santos DM, Parker NH, et al. Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy. Cancer Immunol Res. 2023;11(6):707–19. https://doi.org/10.1158/2326-6066.CIR-22-0487.CrossRefPubMedPubMedCentral
58.
go back to reference Valtis YK, Devlin S, Shouval R, et al. Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes. Blood Adv. 2025;9(1):151–61. https://doi.org/10.1182/bloodadvances.2024014555.CrossRefPubMed
Valtis YK, Devlin S, Shouval R, et al. Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes. Blood Adv. 2025;9(1):151–61. https://doi.org/10.1182/bloodadvances.2024014555.CrossRefPubMed
59.
go back to reference Derman BA, Kordas K, Ridgeway J, et al. Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. Blood Adv. 2019;3(22):3488–98. https://doi.org/10.1182/bloodadvances.2019000790.CrossRefPubMedPubMedCentral
Derman BA, Kordas K, Ridgeway J, et al. Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. Blood Adv. 2019;3(22):3488–98. https://doi.org/10.1182/bloodadvances.2019000790.CrossRefPubMedPubMedCentral
60.
go back to reference Lin RJ, Kim SJ, Brown S, et al. Phase II study of longitudinal geriatric assessment with risk-adapted interventions to reduce non-relapse mortality in allogeneic hematopoietic cell transplantation for older patients with advanced myeloid malignancies. Blood. 2025;144(Supplement 1):686. https://doi.org/10.1182/blood-2024-207934.CrossRef
Lin RJ, Kim SJ, Brown S, et al. Phase II study of longitudinal geriatric assessment with risk-adapted interventions to reduce non-relapse mortality in allogeneic hematopoietic cell transplantation for older patients with advanced myeloid malignancies. Blood. 2025;144(Supplement 1):686. https://doi.org/10.1182/blood-2024-207934.CrossRef
61.
go back to reference Lin RJ, Kim SJ, Brown S, et al. Prospective geriatric assessment and geriatric consultation in CAR T-cell therapy for older patients with lymphoma. Blood Adv. 2023;7(14):3501–5. https://doi.org/10.1182/bloodadvances.2023010003.CrossRefPubMedPubMedCentral
Lin RJ, Kim SJ, Brown S, et al. Prospective geriatric assessment and geriatric consultation in CAR T-cell therapy for older patients with lymphoma. Blood Adv. 2023;7(14):3501–5. https://doi.org/10.1182/bloodadvances.2023010003.CrossRefPubMedPubMedCentral
62.
go back to reference Yates SJ, Cursio JF, Artz A, et al. Optimization of older adults by a geriatric assessment-guided multidisciplinary clinic before CAR T-cell therapy. Blood Adv. 2024;8(14):3785–97. https://doi.org/10.1182/bloodadvances.2024012727.CrossRefPubMedPubMedCentral
Yates SJ, Cursio JF, Artz A, et al. Optimization of older adults by a geriatric assessment-guided multidisciplinary clinic before CAR T-cell therapy. Blood Adv. 2024;8(14):3785–97. https://doi.org/10.1182/bloodadvances.2024012727.CrossRefPubMedPubMedCentral
63.
go back to reference Olin RL, Fretham C, Pasquini MC, et al. Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. Blood Adv. 2020;4(12):2810–20. https://doi.org/10.1182/bloodadvances.2020001719.CrossRefPubMedPubMedCentral
Olin RL, Fretham C, Pasquini MC, et al. Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. Blood Adv. 2020;4(12):2810–20. https://doi.org/10.1182/bloodadvances.2020001719.CrossRefPubMedPubMedCentral
64.
go back to reference Deschler B, Ihorst G, Schnitzler S, et al. Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis. Bone Marrow Transplant. 2018;53(5):565–75. https://doi.org/10.1038/s41409-017-0021-4.CrossRefPubMed
Deschler B, Ihorst G, Schnitzler S, et al. Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis. Bone Marrow Transplant. 2018;53(5):565–75. https://doi.org/10.1038/s41409-017-0021-4.CrossRefPubMed
65.
go back to reference Alibhai SM, Durbano S, Breunis H, et al. A phase II exercise randomized controlled trial for patients with acute myeloid leukemia undergoing induction chemotherapy. Leuk Res. 2015;S0145–2126(15):30365–9. https://doi.org/10.1016/j.leukres.2015.08.012.CrossRef
Alibhai SM, Durbano S, Breunis H, et al. A phase II exercise randomized controlled trial for patients with acute myeloid leukemia undergoing induction chemotherapy. Leuk Res. 2015;S0145–2126(15):30365–9. https://doi.org/10.1016/j.leukres.2015.08.012.CrossRef
66.
go back to reference Klepin HD, Danhauer SC, Tooze JA, et al. Exercise for older adult inpatients with acute myelogenous leukemia: A pilot study. J Geriatr Oncol. 2011;2(1):11–7. https://doi.org/10.1016/j.jgo.2010.10.004.CrossRefPubMedPubMedCentral
Klepin HD, Danhauer SC, Tooze JA, et al. Exercise for older adult inpatients with acute myelogenous leukemia: A pilot study. J Geriatr Oncol. 2011;2(1):11–7. https://doi.org/10.1016/j.jgo.2010.10.004.CrossRefPubMedPubMedCentral
67.
go back to reference Loh KP, Sanapala C, Di Giovanni G, et al. Developing and adapting a mobile health exercise intervention for older patients with myeloid neoplasms: A qualitative study. J Geriatr Oncol. 2021;12(6):909–14. https://doi.org/10.1016/j.jgo.2021.02.023.CrossRefPubMedPubMedCentral
Loh KP, Sanapala C, Di Giovanni G, et al. Developing and adapting a mobile health exercise intervention for older patients with myeloid neoplasms: A qualitative study. J Geriatr Oncol. 2021;12(6):909–14. https://doi.org/10.1016/j.jgo.2021.02.023.CrossRefPubMedPubMedCentral
68.
go back to reference Salas MQ, González RS, Mestre C, et al. Transforming Frailty Care in Allo-HCT Candidates: A Prospective Assessment of a Tele-Prehabilitation Project. Blood. 2024;144(Supplement 1):787. https://doi.org/10.1182/blood-2024-204867.CrossRef
Salas MQ, González RS, Mestre C, et al. Transforming Frailty Care in Allo-HCT Candidates: A Prospective Assessment of a Tele-Prehabilitation Project. Blood. 2024;144(Supplement 1):787. https://doi.org/10.1182/blood-2024-204867.CrossRef
69.
go back to reference Jayani R, Rosko A, Olin R, et al. Use of geriatric assessment in hematopoietic cell transplant. J Geriatr Oncol. 2020;11(2):225–36. https://doi.org/10.1016/j.jgo.2019.09.012.CrossRefPubMed
Jayani R, Rosko A, Olin R, et al. Use of geriatric assessment in hematopoietic cell transplant. J Geriatr Oncol. 2020;11(2):225–36. https://doi.org/10.1016/j.jgo.2019.09.012.CrossRefPubMed
70.
go back to reference Kennedy VE, Olin RL. Haematopoietic stem-cell transplantation in older adults: geriatric assessment, donor considerations, and optimisation of care. Lancet Haematol. 2021;8(11):e853–61. https://doi.org/10.1016/S2352-3026(21)00231-3.CrossRefPubMed
Kennedy VE, Olin RL. Haematopoietic stem-cell transplantation in older adults: geriatric assessment, donor considerations, and optimisation of care. Lancet Haematol. 2021;8(11):e853–61. https://doi.org/10.1016/S2352-3026(21)00231-3.CrossRefPubMed
71.
go back to reference Neuendorff NR, Khan A, Ullrich F, et al. Cellular therapies in older adults with hematological malignancies: A case-based, state-of-the-art review. J Geriatr Oncol. 2024;15(3):101734. https://doi.org/10.1016/j.jgo.2024.101734.CrossRefPubMed
Neuendorff NR, Khan A, Ullrich F, et al. Cellular therapies in older adults with hematological malignancies: A case-based, state-of-the-art review. J Geriatr Oncol. 2024;15(3):101734. https://doi.org/10.1016/j.jgo.2024.101734.CrossRefPubMed
72.
go back to reference Jayani RV. How old is too old? Frailty and geriatric assessments of older patients undergoing allogeneic HCT. Hematol Am Soc Hematol Educ Program. 2023;2023(1):709–14. https://doi.org/10.1182/hematology.2023000457.CrossRef
Jayani RV. How old is too old? Frailty and geriatric assessments of older patients undergoing allogeneic HCT. Hematol Am Soc Hematol Educ Program. 2023;2023(1):709–14. https://doi.org/10.1182/hematology.2023000457.CrossRef
73.
go back to reference Stella F, Marasco V, Levati GV, et al. Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial. Blood Adv. 2023;7(19):5996–6004. https://doi.org/10.1182/bloodadvances.2023010348.CrossRefPubMedPubMedCentral
Stella F, Marasco V, Levati GV, et al. Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial. Blood Adv. 2023;7(19):5996–6004. https://doi.org/10.1182/bloodadvances.2023010348.CrossRefPubMedPubMedCentral
Metadata
- Title
- Role of Geriatric Assessment in Hematopoietic Stem Cell Transplant and Cellular Therapies
- Authors
-
Lawrence Cheng Kiat Ng
Rachel Qiao Ming Ng
Joseph DiTursi
Kah Poh Loh
- Publication date
- 10-04-2025
- Publisher
- Springer US
- Keywords
- Geriatric Assessment
Stem Cell Transplantation
Stem Cell Transplantion
Stem Cell Transplantation - Published in
-
Current Treatment Options in Oncology
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277 - DOI
- https://doi.org/10.1007/s11864-025-01316-6
Image Credits
Stylized collage of women/© (M) VictoriaBar / Getty Images / iStock, Genetic code/© Springer Healthcare, Aplastic Anemia/© Springer Healthcare IME